Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07851025 |
| Title | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer (TREVI-OC-02) |
| Acronym | TREVI-OC-02 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | SVN | SVK | ITA | ISR | GRC | ESP | DEU | CAN | BRA | BGR | AUS | ARG |